Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab Extension in Ankylosing Spondylitis (MEASURE 1 Extension)
NCT01863732Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2013
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in ankylosing spondylitis (AS) (2 arms), sponsored by Novartis. Primary endpoint: Assessment of Spondyloarthritis International Society 20 Response. Started Nov 2013; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT01863732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01863732.